Full video transcriptClick to expand
Auto-generated transcript of @nicolegrecopeepas's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00So I'm here with Dr. Elisa and it's finally the day. I'm excited. I'm seeing my blood work. It did have
- 0:07normal cycle this time. It might not always be a normal cycle, but this time it was a normal cycle. Especially at this age. Yeah.
- 0:13Yeah, so when it comes to hormonal changes a lot of times what we notice with the blood work is there's something called
- 0:19follicle stimulating hormone, luteinizing hormone. They do trigger the release of an egg and
- 0:23we are born with a defined number of eggs. So
- 0:26what happens is eventually these numbers go up and up and up because they're looking for eggs that are not there.
- 0:31Got it. So you had that in the past this time you did it. So it found an egg and
- 0:37I better be careful, Doc.
- 0:40Yes, definitely make good life choices. That's it.
- 0:43Yeah, so eventually when that happens we do start, sometimes start people on hormone replacement. All of times we do it based on symptoms.
- 0:49A lot of times hormone replacement looks different for different people and every time we do this blood work every three or four months
- 0:55we have to change something in certain ones. It's involved.
- 0:59Estridile progesterone is the most commonly replaced thing. Sometimes we do find that people need testosterone as well.
- 1:04Nickel your testosterone is awesome. You absolutely don't need that.
- 1:07But yeah, that's what it comes down to and then we do monitor every three months wall and hormone replacement. The
- 1:12IGF-1 so the thing affected by the epimarelle and slash tesimarelle and that your auntie is going up.
- 1:17So we went up from 124 to 140. That's actually working. So we'll be doing some more shots today. And thyroid is perfect. Perfect.
- 1:24One of the best blood works today. Hey, thanks, Dr. Lisa.
- 1:26I win.
- 1:27Thank you.
@nicolegrecopeepas's peptide and HRT claims, fact-checked
Quick answer
Nicole appears to be in perimenopause based on the discussion of variable FSH and LH levels and occasional anovulatory cycles, with her physician noting she had a normal ovulatory cycle this month. She is being monitored quarterly on a protocol including ipamorelin and tesamorelin, with IGF-1 used as a surrogate marker for growth hormone axis activity. Her thyroid and testosterone panels were described as within normal limits, and HRT has not yet been initiated based on her current symptom profile.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @nicolegrecopeepas's peptide and HRT claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
EGRIFTA (tesamorelin for injection) FDA Prescribing Information
FDA-approved label for tesamorelin (NDA 022505), indicated to reduce excess abdominal fat in HIV patients with lipodystrophy.
FDA
Egrifta (tesamorelin) Original NDA 022505 FDA Approval Letter
FDA approval letter marking the first approved drug for HIV-associated lipodystrophy.
FDA
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@nicolegrecopeepas's peptide and HRT claims, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this ipamorelin video claims cluster
Best for searchers comparing ipamorelin claims with CJC-1295, sermorelin, and growth-hormone peptide evidence.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@nicolegrecopeepas's peptide and HRT claims, fact-checked" from Nicole Greco-Peepas. We read the clip as a Peptide social video fact-checks claim about Ipamorelin, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Nicole appears to be in perimenopause based on the discussion of variable FSH and LH levels and occasional anovulatory cycles, with her physician noting she had a normal ovulatory cycle this month.
The reason this review is not generic is the source wording and the canonical claim label "peptides let s talk hormone replacement peptides and go over my bloo." In this clip, the useful excerpt is: "So I'm here with Dr." That wording changes the review because it points to Ipamorelin evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against EGRIFTA (tesamorelin for injection) FDA Prescribing Information (2024), Egrifta (tesamorelin) Original NDA 022505 FDA Approval Letter (2010), and Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial (2010), plus the creator's own wording. Ipamorelin decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Nicole appears to be in perimenopause based on the discussion of variable FSH and LH levels and occasional anovulatory cycles, with her physician noting she had a normal ovulatory cycle this month.
FormBlends verdict
Ipamorelin evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Nicole appears to be in perimenopause based on the discussion of variable FSH and LH levels and occasional anovulatory cycles, with her physician noting she had a normal ovulatory cycle this month. She is being monitored quarterly on a protocol including ipamorelin and tesamorelin, with IGF-1 used as a surrogate marker for growth hormone axis activity. Her thyroid and testosterone panels were described as within normal limits, and HRT has not yet been initiated based on her current symptom profile.
- FSH above 25 IU/L on two draws 60 days apart is one clinical marker of menopause transition, but single-cycle variability is common and well-documented by the STRAW+10 framework (Harlow et al., 2012, Climacteric).
- Ipamorelin is not FDA-approved for longevity or body composition. It is a synthetic peptide used off-label as a growth hormone secretagogue, meaning all use outside HIV-lipodystrophy indications is experimental.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- FSH above 25 IU/L on two draws 60 days apart is one clinical marker of menopause transition, but single-cycle variability is common and well-documented by the STRAW+10 framework (Harlow et al., 2012, Climacteric).
- Ipamorelin is not FDA-approved for longevity or body composition. It is a synthetic peptide used off-label as a growth hormone secretagogue, meaning all use outside HIV-lipodystrophy indications is experimental.
- A 16-point rise in IGF-1 (124 to 140 ng/mL) falls within normal biological variability and should not be interpreted as confirmed proof of peptide efficacy without controlling for diet, sleep, and cycle phase.
- Chronically elevated IGF-1 above the upper normal range has been associated with increased colorectal, breast, and prostate cancer risk in epidemiological data (Renehan et al., 2004, Lancet). Monitoring matters.
- The Menopause Society (2023) recommends against initiating HRT based on labs alone; symptoms should drive the decision, which is exactly what this physician described.
- Quarterly IGF-1 and hormone monitoring while on peptide and HRT protocols is a reasonable safety practice, and the fact that this clinic does it is above average for this space.
- Testosterone therapy for women requires documented deficiency and symptom correlation before initiating; the doctor declining to prescribe it here despite patient interest reflects appropriate clinical judgment.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @nicolegrecopeepas actually say?
This is a clinical consultation clip, not a hype reel, which puts it in a different category than most peptide content. Nicole sits with a physician identified as "Dr. Elisa" and reviews actual lab results. The doctor explains that rising FSH and LH levels signal the ovaries are running low on eggs, that hormone replacement is symptom-driven and individualized, and that Nicole's IGF-1 went from 124 to 140, which the doctor attributes to ipamorelin and tesamorelin. Nicole is also told her testosterone and thyroid panels are normal. No specific doses are named, no miracle outcomes are promised. That restraint matters.
The framing is mostly responsible. The doctor says "sometimes" when discussing who gets started on HRT, and explicitly notes that protocols change every three to four months. Nicole is told to "make good life choices" regarding pregnancy risk, which gets a laugh but is actually medically appropriate advice given her FSH normalized this cycle.
Does the science back this up?
Mostly, yes, on the hormone side. The FSH/LH explanation is textbook perimenopause physiology and is well-supported in the literature. Soules et al. (2001, Menopause) established the STRAW staging system that describes exactly this pattern of rising gonadotropins as ovarian reserve declines. The claim that estradiol and progesterone are "the most commonly replaced" hormones in this population is accurate, consistent with the Menopause Society's 2023 position statement.
The IGF-1 increase is where things get more complicated. A rise from 124 to 140 ng/mL is real and measurable, and growth hormone secretagogues like ipamorelin do stimulate GH release, which drives IGF-1 production. Sigalos and Pastuszak (2018, Sexual Medicine Reviews) confirmed this mechanism in a review of GH secretagogues. However, attributing that specific numerical change to these peptides requires ruling out confounders including diet, sleep, and cycle phase, none of which are addressed in the clip.
What did they get wrong (or right)?
The FSH and LH explanation is accurate but slightly incomplete. The doctor says these hormones "trigger the release of an egg," which is true, but their more important role in this context is stimulating follicular development. The distinction matters for patients trying to understand why they might still ovulate sporadically even with elevated FSH. This is not a dangerous error, but it is an oversimplification.
The IGF-1 attribution is the weakest link here. A 16-point rise in IGF-1 is within normal intra-individual variability. Clemmons (2011, Nature Reviews Endocrinology) noted that IGF-1 can fluctuate 20 to 30 percent based on nutritional status alone. The doctor says "that's actually working" with confidence that the data does not fully support. It might be working. It also might be noise. Presenting it as confirmed efficacy to an audience of nearly 10,000 viewers is a stretch.
What they got right: the emphasis on individualized protocols, quarterly monitoring, and not pushing testosterone on someone who does not need it. That last point is refreshingly honest for this content category.
What should you actually know?
If you are a woman in perimenopause, the FSH and LH explanation here is genuinely useful. These hormones do rise as egg reserves decline, and that rise is one of the markers clinicians use to assess where you are in the transition. The Menopause Society recommends against using FSH alone to diagnose menopause, precisely because of the variability Nicole demonstrates this cycle, but serial measurements add real information.
On peptides: ipamorelin is a synthetic growth hormone secretagogue. It is not FDA-approved for anti-aging or body composition. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Using either off-label carries regulatory and safety considerations your prescriber should walk you through in detail. IGF-1 monitoring is appropriate when using these compounds, and the fact that this practice does it quarterly is a reasonable safety practice. Chronically elevated IGF-1 has been associated with increased cancer risk in epidemiological studies, including a meta-analysis by Renehan et al. (2004, Lancet).
Do not interpret a single IGF-1 data point as proof a peptide protocol is working. Ask your provider for trending data across multiple draws before drawing conclusions.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Nicole Greco-Peepas · Instagram creator
9.0K views on this video
Let’s talk hormone replacement, peptides and go over my blood work. Ladies make sure you watch the whole reel. #nicolepeepas #ngpbro #ngpmethod #hormonereplacement #Peptides #madisonmedicalandsports
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about fsh above 25 iu/l on two draws 60 days apart?
FSH above 25 IU/L on two draws 60 days apart is one clinical marker of menopause transition, but single-cycle variability is common and well-documented by the STRAW+10 framework (Harlow et al., 2012, Climacteric).
What does the video say about ipamorelin?
Ipamorelin is not FDA-approved for longevity or body composition. It is a synthetic peptide used off-label as a growth hormone secretagogue, meaning all use outside HIV-lipodystrophy indications is experimental.
What does the video say about a 16-point rise in igf-1 (124 to 140 ng/ml) falls?
A 16-point rise in IGF-1 (124 to 140 ng/mL) falls within normal biological variability and should not be interpreted as confirmed proof of peptide efficacy without controlling for diet, sleep, and cycle phase.
What does the video say about chronically elevated igf-1 above the upper normal range has been?
Chronically elevated IGF-1 above the upper normal range has been associated with increased colorectal, breast, and prostate cancer risk in epidemiological data (Renehan et al., 2004, Lancet). Monitoring matters.
What does the video say about the menopause society (2023) recommends against initiating hrt based on?
The Menopause Society (2023) recommends against initiating HRT based on labs alone; symptoms should drive the decision, which is exactly what this physician described.
What does the video say about quarterly igf-1?
Quarterly IGF-1 and hormone monitoring while on peptide and HRT protocols is a reasonable safety practice, and the fact that this clinic does it is above average for this space.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Nicole Greco-Peepas, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.